

DATE: 1-15-69

HENRY J. LAY, JR., M.D.
Commissioner of Food and Drugs
Dept. of Health, Education, & Welfare
Washington, D.C. 20204

Dear Doctor Lay:

Kysteclin-F has had a definite useful place among the antibiotics prescribed in my practice, particularly for those types of patients prone to candidal infections (women with a history of candidiasis, elderly patients, diabetics, patients on corticosteroids, etc.)

The FDA order to withdraw Kysteclin-F from availability for prescription use would create an unnecessary and inconvenient restriction on my prescribing freedom to the detriment of my patients.

Sincerely yours,

V. D. Platt M.D.

*I have not had any incidence
of monilia infection while using
Kysteclin-F.*
V. D. Platt